MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced that data from the double-blind, randomized satraplatin Phase 3 trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) are being presented at the 2009 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, Florida. The SPARC trial evaluated satraplatin plus prednisone versus placebo plus prednisone in 950 patients with androgen-independent or castrate-refractory prostate cancer (CRPC) who had progressed after initial chemotherapy. The data being presented today are the result of pre-specified exploratory analyses of the SPARC trial, and they show an improvement in overall survival in a subset of patients refractory to docetaxel.
